I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C. Wainwright reaffirmed its Buy rating and $50 price target on Assembly Biosciences (NASDAQ:ASMB) following the company’s presentation of interim data for ABI-5366, a long-acting oral treatment for recurrent genital herpes. H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data Source:unsplash Presented data showed strong antiviral activity, favo ...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for 22.4 million shares. The company raised $31 million in gross proceeds from the offering. Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase Investors who exercised the warrants, issued in March and August of last year, are poised to receive new register ...

A downtrend has been apparent in Beam Therapeutics Inc. (BEAM) lately. While the stock has lost 11.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the fut ...

临床试验进展 - 公司宣布其主导的广谱抗病毒候选药物ProLectin-M第二项随机双盲、安慰剂对照临床试验已成功完成[1] - 此次试验旨在确认早期第二阶段研究的突破性结果，该结果显示ProLectin-M在不到一周内使治疗参与者的聚合酶链式反应（PCR）和感染达到检测不到的水平[2] - 第三次独立试验的成功执行为ProLectin-M作为快速起效的口服疗法提供了有力证据[2] 药物数据与监管沟通 - 试验数据预计将用于向印度中央药品标准控制组织（CDSCO）通报第三阶段试验设计，并将根据要求提交给美国食品药品监督管理局（FDA）[1] - 详细的安全性和有效性终点等全面数据预计将被汇编，并在未来几周内提交至同行评审的医学期刊发表[3] 药物特性与行业定位 - ProLectin-M被定位为首个基于糖化学的口服抗病毒药物[4][6] - 该药物在多次试验中 consistently 在短时间内靶向达到PCR检测不到的病毒存在，有望从根本上改变全球应对病毒爆发的方式[4] - 公司致力于开发基于线性复合碳水化合物的疗法，以解决抗病毒平台技术中未满足的关键医疗需求[5]

Several biotech and healthcare stocks posted notable gains in after-hours trading, driven by clinical updates, strategic deals, and regulatory milestones. Below is a quick rundown of the top movers and the catalysts behind their price action.Genenta Science S.p.A. (GNTA) shares closed at $2.40, down 27.71% during regular trading, but rebounded modestly to $2.45, up 2.08%, in after-hours action. The volatility follows a pair of material announcements. On October 27, Genenta disclosed a $15 million registere ...

October 28, 2025 02:30 PM GMT China Economics | Asia Pacific FYP Outlines Tech and Consumption Goals The 15th FYP outline elevates efficiency and consumption to headline targets, signalling a willingness to shift toward more balanced growth. But execution remains gradual, and reflation remains in a slow burn through 2026-27. What's new vs. the Communiqué: Execution Playbook Demand – achieving a higher consumption share: Supply – more detailed tech roadmap: Macro implications: A more balanced FYP signals a c ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Research firm BTI calls this company an emerging leader in a fight against specific types of kidney disease. Millions of people around the world could be candidates for maze therapeutics main drug candidate. Company expects data from its phase 2 trial in the first quarter of next year.They've got a variety though of different programs trying to solve some of these diseases. Jason Col is the CEO of Maze Therapeutics joining us now here in our San Francisco studio for another CNBC exclusive. Jason, good to ha ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT ) is buoyant in trading today—up 30%, to a price of $26—its highest value since August 2022—after the company released its Q3 earnings .The group is for both ...